Facing claims of unlawful marketing of the drugs Aranesp and Enbrel, Amgen has agreed to a $71 million settlement with 48 states and the District of Columbia.
The consent judgment was announced last week, Law360 reports. The settlement resolved claims that Amgen had marketed Aranesp (darbepoetin alfa) for cancer-related anemia without FDA approval and had promoted Enbrel (etarnecept) to treat mild plaque psoriasis though Enbrel is approved only for moderate to severe cases of the autoimmune disorder that causes scaling and flaking of the skin. More Drug Maker Amgen Agrees to $71 Million Settlement of Claims of Unlawful Marketing of Aranesp and Enbrel